Seite auswählen

The Indian Patent Office is forcing the German pharmaceutical company Bayer to transfer a patent to a local generics manufacturer. The medication in question is the cancer drug Nexavar, which is supposed to be produced by Natco and offered at a cheaper price in future. The price for the product is fixed by the Indian authorities.

According to the aid organization Doctors without Borders (MSF), treatments involving the medications will decrease from currently about 5,500 dollars per month to 175 dollars. By way of compensation, Bayer will receive a small royalty payment based on the turnover from Natco.

The decision marks the first forced patent transfer in the history of the emerging nation. Bayer is planning to appeal the order.

 [ilink url=] link to source (FTD)[/ilink]